why choose us

First received: October 13, 2023

Clinical Trial: Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Adenoid Cystic Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Brief Summary: The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

Read more